Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Overcoming resistance to BTK inhibition in CLL

Jennifer Woyach • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Selinexor Vecabrutinib Venetoclax

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, elaborates on overcoming resistance to BTK inhibition in chronic lymphocytic leukemia (CLL) patients, touching on the genetic basis to resistance and promising drugs and targets. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Jennifer Woyach

1:04
6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLL
Jennifer Woyach • 8 Dec 2023
1:18
Pirtobrutinib in patients with CLL/SLL previously exposed to covalent BTKi: insights from BRUIN
Jennifer Woyach • 8 Dec 2023
2:57
LP-168: a novel next-generation BTK inhibitor with dual activity in CLL
Jennifer Woyach • 8 Dec 2023
0:49
BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL
Jennifer Woyach • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals